Alirocumab has a positive effect on low-density lipoprotein cholesterol (LDL-C) levels and appears to be well tolerated in patients with hypercholesterolemia and high cardiovascular risk, according to a sub-analysis of Taiwanese patients enrolled in the ODYSSEY KT* clinical trial.
Intradermal influenza vaccination with a dissolvable microneedle patch was well tolerated with robust antibody responses, as well as being preferred over conventional vaccination with needles and syringes, according to the first-in-human TIV-MNP 2015* study.
Among adult eosinophilic esophagitis (EoE) patients with initial response to steroid therapy and receiving maintenance treatment, loss of treatment response is associated with dose reduction and results in worsening of endoscopic findings, according to a study.
The macrolide antibiotic azithromycin may be an effective adjunctive therapy for individuals whose asthma symptoms persist despite treatment with corticosteroids and bronchodilators, a recent study found.
Increasing the dose of loop diuretic at hospital discharge of patients with heart failure (HF) was not associated with a reduced risk of hospital readmission for HF or any cause, in contrary to previous reports suggesting that such a dosing strategy could reduce readmission, according to a study presented at the 21st Asia Pacific Society of Cardiology Congress (APSC 2017) in Singapore.
Despite progression, lean body mass and skeletal muscle mass have increased while the systemic inflammatory response has remained stable in gastrointestinal (GI) cancer patients with cachexia receiving fish oil (FO)-enriched nutrition, a new retrospective cohort study reveals.
Dr Lesley Braun, Blackmores Institute Director,
is interviewed and answers some critical questions
on complementary medicine, its evolution, its
benefits and its present and future roles alongside
Elderly persons (≥75 years) on aspirin-based antiplatelet therapy without routine proton-pump inhibitor (PPI) use have a higher long-term risk of major bleeding, in particular upper gastrointestinal (GI) bleeding which is often more disabling or fatal than in younger persons, according to the OXVASC* study.
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.